Cryosite Limited (ASX:CTE)

Market Cap	61.01M +45.3%
Revenue (ttm)	16.70M +18.3%
Net Income	2.24M +18.6%
EPS	0.04 +14.8%
Shares Out	48.81M
PE Ratio	28.80
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,282
Open	1.250
Previous Close	1.250
Day's Range	1.250 - 1.250
52-Week Range	0.800 - 1.400
Beta	0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 9, 2026

About Cryosite

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements. The Ultra-frozen and cryogenic segment offers advanced therapy medicinal products (ATMPS), such as cell ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1999
• Employees: 27
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CTE

Financial Performance

In fiscal year 2026, Cryosite's revenue was 16.70 million, an increase of 18.31% compared to the previous year's 14.12 million. Earnings were 2.24 million, an increase of 18.63%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 9, 2026

Data Sources Report a data error